The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.

about

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.

Item

http://www.wikidata.org/entity/Q47835415

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.

@en

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.

@nl

type

Item

label

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.

@en

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.

@nl

prefLabel

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.

@en

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.

@nl

P1476

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.

@en

P2093

Ling Xin

http://www.w3.org/2001/XMLSchema#string

Tracey A Martin

http://www.w3.org/2001/XMLSchema#string

Wen G Jiang

http://www.w3.org/2001/XMLSchema#string

Yin-Hua Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

Gene expression profiling predicts clinical outcome of breast cancer

A gene-expression signature as a predictor of survival in breast cancer

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

The MINDACT trial: the first prospective clinical validation of a genomic tool

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.

Converting a breast cancer microarray signature into a high-throughput diagnostic test.

P304

34-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.14740/WJON1019W

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29147432

http://www.w3.org/2001/XMLSchema#string

P932

5649994

http://www.w3.org/2001/XMLSchema#string